In case 6, a 55-year-old Caucasian woman with a history of RA, SLE, and CREST syndrome was treated with leflunomide at the beginning, and then after her disease activity was not controlled, TNF-α inhibitor adalimumab at 40 mg subcutaneously was added. This evidence concerns the gene TNF and rheumatoid arthritis.